Renovacor Announces the Appointment of Matt Killeen, Ph.D., as Chief Scientific Officer

Renovacor Announces the Appointment of Matt Killeen, Ph.D., as Chief Scientific Officer

Aug 25, 2021

PHILADELPHIA, August 25, 2021 (GLOBE NEWSWIRE) — Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Matt Killeen, Ph.D., as chief scientific officer (CSO), effective as of September 1, 2021.